Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Reboxetine by Axsome Therapeutics for Type 1 Narcolepsy (Narcolepsy with Cataplexy): Likelihood of Approval
Reboxetine is under clinical development by Axsome Therapeutics and currently in Phase III for Type 1 Narcolepsy (Narcolepsy with Cataplexy)....
Data Insights
Risk adjusted net present value: What is the current valuation of Axsome Therapeutics's Reboxetine?
Reboxetine is a small molecule commercialized by Axsome Therapeutics, with a leading Phase III program in Type 1 Narcolepsy (Narcolepsy...